AIMS/HYPOTHESIS: We assessed the utility of the OGTT and random plasma glucose concentrations in predicting the time to diagnosis of type 1 diabetes. METHODS: A population-derived cohort of 14,876 newborns with HLA-conferred risk of type 1 diabetes were invited to regular follow-up for islet autoantibodies. When two or more autoantibodies were detected, an OGTT was performed once a year and random plasma glucose analysed twice a year. During follow-up, 567 children developed multiple autoantibodies, 255 (45%) of whom were diagnosed with type 1 diabetes, while 312 remained non-diabetic by December 2011. RESULTS: Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) were risk factors for type 1 diabetes (HR 3.2 [95% CI 1.5, 7.0] and 8.3 [95% CI 6.0, 11.5], respectively). When a random plasma glucose value ≥ 7.8 mmol/l was observed, the HR for diabetes was 6.0 (95% CI 4.3, 8.6). The median time to diagnosis after the detection of IFG was 5.2 years (interquartile range [IQR] 3.4, 6.3); after IGT, 0.7 years (IQR 0.3, 1.9); and, after a random plasma glucose ≥ 7.8 mmol/l, 1.0 years (IQR 0.3, 1.5). In a retrospective analysis, both OGTT-derived 2 h plasma glucose and random plasma glucose started to increase 1.5 years before diagnosis (p < 0.001 and p = 0.004, respectively). CONCLUSIONS/ INTERPRETATION: Dysglycaemia detected in an OGTT or based on random plasma glucose is a useful marker in the prediction of time to onset of type 1 diabetes in high-risk children. Random plasma glucose is a simple and low-cost measurement with comparable predictive characteristics to that of OGTT-derived 2 h glucose.
AIMS/HYPOTHESIS: We assessed the utility of the OGTT and random plasma glucose concentrations in predicting the time to diagnosis of type 1 diabetes. METHODS: A population-derived cohort of 14,876 newborns with HLA-conferred risk of type 1 diabetes were invited to regular follow-up for islet autoantibodies. When two or more autoantibodies were detected, an OGTT was performed once a year and random plasma glucose analysed twice a year. During follow-up, 567 children developed multiple autoantibodies, 255 (45%) of whom were diagnosed with type 1 diabetes, while 312 remained non-diabetic by December 2011. RESULTS: Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) were risk factors for type 1 diabetes (HR 3.2 [95% CI 1.5, 7.0] and 8.3 [95% CI 6.0, 11.5], respectively). When a random plasma glucose value ≥ 7.8 mmol/l was observed, the HR for diabetes was 6.0 (95% CI 4.3, 8.6). The median time to diagnosis after the detection of IFG was 5.2 years (interquartile range [IQR] 3.4, 6.3); after IGT, 0.7 years (IQR 0.3, 1.9); and, after a random plasma glucose ≥ 7.8 mmol/l, 1.0 years (IQR 0.3, 1.5). In a retrospective analysis, both OGTT-derived 2 h plasma glucose and random plasma glucose started to increase 1.5 years before diagnosis (p < 0.001 and p = 0.004, respectively). CONCLUSIONS/ INTERPRETATION: Dysglycaemia detected in an OGTT or based on random plasma glucose is a useful marker in the prediction of time to onset of type 1 diabetes in high-risk children. Random plasma glucose is a simple and low-cost measurement with comparable predictive characteristics to that of OGTT-derived 2 h glucose.
Authors: R Hermann; M Knip; R Veijola; O Simell; A-P Laine; H K Akerblom; P-H Groop; C Forsblom; K Pettersson-Fernholm; J Ilonen Journal: Diabetologia Date: 2003-03-18 Impact factor: 10.122
Authors: V Parikka; K Näntö-Salonen; M Saarinen; T Simell; J Ilonen; H Hyöty; R Veijola; M Knip; O Simell Journal: Diabetologia Date: 2012-03-23 Impact factor: 10.122
Authors: Jay M Sosenko; Jerry P Palmer; Carla J Greenbaum; Jeffrey Mahon; Catherine Cowie; Jeffrey P Krischer; H Peter Chase; Neil H White; Bruce Buckingham; Kevan C Herold; David Cuthbertson; Jay S Skyler Journal: Diabetes Care Date: 2006-03 Impact factor: 19.112
Authors: Theresa A Aly; Akane Ide; Mohamed M Jahromi; Jennifer M Barker; Maria S Fernando; Sunanda R Babu; Liping Yu; Dongmei Miao; Henry A Erlich; Pamela R Fain; Katherine J Barriga; Jill M Norris; Marian J Rewers; George S Eisenbarth Journal: Proc Natl Acad Sci U S A Date: 2006-09-11 Impact factor: 11.205
Authors: Kirsti Näntö-Salonen; Antti Kupila; Satu Simell; Heli Siljander; Tiina Salonsaari; Anne Hekkala; Sari Korhonen; Risto Erkkola; Jukka I Sipilä; Lotta Haavisto; Marja Siltala; Juhani Tuominen; Jari Hakalax; Heikki Hyöty; Jorma Ilonen; Riitta Veijola; Tuula Simell; Mikael Knip; Olli Simell Journal: Lancet Date: 2008-09-22 Impact factor: 79.321
Authors: Giulia Frazzei; Ronald F van Vollenhoven; Brigit A de Jong; Sarah E Siegelaar; Dirkjan van Schaardenburg Journal: Front Immunol Date: 2022-06-30 Impact factor: 8.786
Authors: Laura M Jacobsen; Kendra Vehik; Riitta Veijola; Katharina Warncke; Jorma Toppari; Andrea K Steck; Patricia Gesualdo; Beena Akolkar; Markus Lundgren; William A Hagopian; Jin-Xiong She; Marian Rewers; Anette-G Ziegler; Jeffrey P Krischer; Helena Elding Larsson; Michael J Haller Journal: Diabetes Care Date: 2022-03-01 Impact factor: 17.152
Authors: Maarit K Koskinen; Olli Helminen; Jaakko Matomäki; Susanna Aspholm; Juha Mykkänen; Marjaana Mäkinen; Ville Simell; Mari Vähä-Mäkilä; Tuula Simell; Jorma Ilonen; Mikael Knip; Riitta Veijola; Jorma Toppari; Olli Simell Journal: Eur J Endocrinol Date: 2015-11-30 Impact factor: 6.664
Authors: Maria Månsson Martinez; Falastin Salami; Helena Elding Larsson; Jorma Toppari; Åke Lernmark; Jukka Kero; Riitta Veijola; Jaakko J Koskenniemi; Päivi Tossavainen; Markus Lundgren; Henrik Borg; Anastasia Katsarou; Marlena Maziarz; Carina Törn Journal: Endocrinol Diabetes Metab Date: 2020-11-05
Authors: Sriya Subramani; Andrew M Bellizzi; Nicholas Borcherding; Simon C Kao; Joseph Dillon; James Howe; Andrew W Norris; Michael J Tansey; Catherina T Pinnaro Journal: Clin Case Rep Date: 2021-09-24